Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rossella Barni"'
Autor:
Francesca Rossi, Elisabetta Gianazza, Enrico Pogliani, Philipp le Coutre, Josef Brueggen, Robert Cozens, Massimo Zucchetti, Rossella Barni, Gonçalo Cabrita, Gianmarco Corneo, Franca Formelli, Pietro Pioltelli, Carlo Gambacorti-Passerini, Loredana Cleris, Maurizio D'Incalci
Publikováno v:
Journal of the National Cancer Institute. 92:1641-1650
BACKGROUND Chronic myeloid leukemia is caused by a chromosomal translocation that results in an oncogenic fusion protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity is inhibited by the antineoplastic drug STI571. This drug can cure mice giv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db046324a0aec639a5382061cc9172d
https://doi.org/10.1093/jnci/92.20.1641
https://doi.org/10.1093/jnci/92.20.1641
Autor:
Rossella, Barni, Silvia, Bolzoni, Chiara, Bonazzi, Rossella, Burani, Giuseppe, Del Corno, Anna, Galetti, Carlo, Maggioni, Guia, Marinoni, Anna, Pavan, Elena, Pirola, Firouzeh, Setoud
Publikováno v:
Igiene e sanita pubblica. 58(1-2)
This study examines the early data of a breast cancer screening campaign (Progetto Donna) set up by the Milan Health Unit 1 in 1999. The authors have focused on some basic organizational aspects of such campaign and the patients' high response to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d323de36c056dc5ff04b1970f8ee980
https://pubmed.ncbi.nlm.nih.gov/12904821
https://pubmed.ncbi.nlm.nih.gov/12904821
Autor:
Gian Marco Corneo, Enrico Pogliani, Edoardo Marchesi, Carlo Gambacorti-Passerini, Pietro Pioltelli, Magda Verga, Rossella Barni, Fabio Rossi, Francesca Rossi
Publikováno v:
British journal of haematology. 112(4)
STI571 (CGP57148B) is an inhibitor of BCR/ABL, the cause of chronic myeloid leukaemia (CML). A difference exists between CML patients in chronic phase, in which responses to STI571are durable, and patients in blast crisis, who generally experience on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c82d6f8d59c98621a3b290b8ab5e1f26
https://pubmed.ncbi.nlm.nih.gov/11298594
https://pubmed.ncbi.nlm.nih.gov/11298594
Autor:
Rosanna Supino, Gonçalo Cabrita, Rossella Barni, Philipp le Coutre, Carlo Gambacorti-Passerini, Marileila Varella-Garcia, Elena Tassi, Luca Mologni, Edoardo Marchesi
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
The 2-phenylaminopyrimidine derivative STI571 has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr/abl fusion protein. The activity of this inhibitor has been demonstrated so far both in vitro with bcr/abl expressing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::285ad6f1ee9171219fe79e42800fd1c3
https://pubmed.ncbi.nlm.nih.gov/11186275
https://pubmed.ncbi.nlm.nih.gov/11186275